Navigation Links
Predicting the future in ovarian cancer
Date:11/14/2007

Kisspeptin and its receptor GPR54 predict a favourable clinical outcome in women with ovarian carcinoma, and are specific for the clear cell carcinoma subtype, research published this week in the online open access journal, BMC Medicine, reveals.

The kisspeptins, a family of peptide hormones, and the receptor GPR54 have previously been associated with anti-metastatic activity in certain human tumours. In this study, researchers have shown that kisspeptin and GPR54 are independent prognostic biomarkers specific for ovarian clear cell carcinoma - the first such markers to be identified.

A research team based at the BC Cancer Agency and Vancouver General Hospital, Vancouver, Canada created a tissue microarray - paraffin blocks which allow numerous tissue samples to be analysed simultaneously - from 518 cases of early-stage ovarian carcinoma. They analysed the samples using antibodies against kisspeptin and the G-protein-coupled receptor GPR54. Cases that showed strong staining for either kisspeptin or GPR54 were scored as positive, the rest negative.

The study revealed that patients who were positive for both kisspeptin and GPR54 had a favourable prognosis as compared to those patients who were negative for both kisspeptin and GPR54 cases - both in terms of disease-specific survival and overall survival. Researchers also found that these molecular markers were significantly associated with the clear cell ovarian carcinomas subtype.

Few prognostic or predictive molecular markers for ovarian cancer exist, yet such markers could be vital for the early diagnosis and management of the disease. The authors propose that in the future, serum kisspeptin levels could provide a means to monitor disease activity, and kisspeptins may even have use as therapeutic agentsin women with ovarian clear cell carcinoma. These possibilities require further research, however.

They write: "We anticipate that the strong association of GPR54 and kisspeptin expression with outcome and clear cell type in ovarian carcinoma will stimulate fresh approaches to what is still a lethally intractable disease."


'/>"/>

Contact: Charlotte Webber
press@biomedcentral.com
44-020-763-19980
BioMed Central
Source:Eurekalert

Related medicine news :

1. Use of certain lipid measures not more effective in predicting coronary heart disease
2. Blood test takes step toward predicting Alzheimers risk, Stanford researchers find
3. Predicting survival after liver transplantation
4. Campaign for Americas Future Memorandum: Katrina Storm Warning
5. Shipcom Partners With DOKUMENTA for METROs Future Store Initiative
6. Johnson & Johnson Campaign for Nursings Future Joins With AACN to Offer New Minority Nurse Faculty Scholars Program
7. American Heart Association Surgical Supplement Journal Report: Appropriate Hospital Discharge System Can Prevent Future Cardiac Events
8. The Humana Foundation and Libraries for the Future Launch Health Literacy Pilot in Atlanta
9. Divorce foretells childs future care for elderly parent
10. Experts Agree. Ohios Technology Investment Future Looks Bright
11. Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... During pregnancy, women are ... erosion, and those dental problems can increase the risk of pregnancy complications. Unfortunately, ... are failing to get the dental care they need. Agoura Hills dentist, Philip ...
(Date:1/17/2017)... ... January 17, 2017 , ... Gym Source, America’s leading retailer ... showroom at South Dixie Hwy in Miami, FL. , “We are elated to be ... new innovative in-store concept is designed to give clients a seamless and motivating shopping ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... improved supplement, Healthful-Flex. , The company, owned and operated by Ed Stroup, ... at a reasonable price with the highest level of customer service. Healthful Balance ...
(Date:1/17/2017)... ... January 17, 2017 , ... Metro Development ... to infusing high speed technology into the fabric of an entire community. A ... of healthcare and wellness in a yet-to-be-named, health focused campus. Leading this initiative ...
(Date:1/17/2017)... ... January 17, 2017 , ... Peoples Health is pleased ... network on Dec. 1, 2016. Peoples Health, a Metairie-based Medicare Advantage company, serves ... exciting addition to our provider network, and the addition will benefit our members ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... 18, 2017 ML Capital ... to publish an online presentation tomorrow, January 19 ... forecast for 2017. Management reports that the forecast ... sales performance from its existing operations, and the ... into the Cannabis sector through a partnership ...
(Date:1/18/2017)... 2017  Astellas Pharma Inc. (President and CEO: ... its participation in Access Accelerated, a global, multi-stakeholder ... prevention, diagnostics and treatment in low-income and lower-middle ... companies and in collaboration with the World Bank ... (UICC), Astellas will work towards the United Nations ...
(Date:1/17/2017)... Jan. 17, 2017 North America Insulin Delivery ... report, "North America Insulin Delivery Market Outlook to 2022", ... Delivery market. The report provides value, in millions of ... within market segments - Insulin Pens, Insulin Pumps, Insulin ... also provides company shares and distribution shares data for ...
Breaking Medicine Technology: